Summary The methyl-thiazol-tetrazolium (MTU) assay is a drug resistance assay which cannot discriminate between malignant and non-malignant cells. We previously reported that samples with > 80% leukaemic cells at the start of culture give similar results in the MTT assay and the differential staining cytotoxicity assay, in which a discrimination between malignant and non-malignant cells can be made. However, the percentage of leukaemic cells may change during culture, which might affect the results of the MTT assay. We studied 106 untreated childhood acute lymphoblastic leukaemia (ALL) samples with > 80% leukaemic cells at the start of culture. This percentage decreased below 80% in 28%, and below 70% in 13%, of the samples after 4 days of culture. A decrease below 70% occurred more often in case of 80-89% leukaemic cells (9/29) than in case of > 90% leukaemic cells at the start of culture (5/77, P = 0.0009). Samples with <70% leukaemic cells after culture were significantly more resistant to 6 out of 13 drugs, and showed a trend towards being more resistant to two more drugs, than samples with > 80% leukaemic cells. No such differences were seen between samples with 70-79% and samples with > 80% leukaemic cells after culture. We next studied in another 30 ALL samples whether contaminating mononuclear cells could be removed by using immunomagnetic beads. Using a beads to target cell ratio of 10:1, the percentage of leukaemic cells increased from mean 72% (s.d. 9.3%) to mean 87% (s.d. 6.7%), with an absolute increase of 2-35%. The recovery of leukaemic cells was mean 82.1% (range 56-100%, s.d. 14.0%). The procedure itself did not influence the results of the MTT assay in three samples containing only leukaemic cells. We conclude that it is important to determine the percentage of leukaemic cells at the start and at the end of the MTT assay and similar drug resistance assays. Contaminating mononuclear cells can be successfully removed from ALL samples using immunomagnetic beads. This approach may increase the number of leukaemic samples which can be evaluated for cellular drug resistance with the MTT assay or a similar cell culture drug resistance assay.
The methyl-thiazol-tetrazolium (MTT) assay is a short-term cell culture drug resistance assay. It is based on the fact that living cells, in contrast to dead cells, can reduce MTT to a coloured formazan product, which is measured spectrophotometrically. The principle was described in 1953 by Black and Speer, while Mosmann described the MTT assay in 1983 in its present semiautomated form. It is a rapid, reliable and objective assay, suited for large-scale patient studies in leukaemia and lymphoma . Therefore, this assay was adapted for drug resistance testing of human leukaemia samples (Hongo et al., 1987; Campling et al., 1988; Pieters et al., 1988; Sargent & Taylor, 1989; Twentyman et al., 1989; Hwang et al., 1993) . The results of this and other tetrazolium salt (e.g. INT)-based cellular drug resistance assays correlate well with the clinical outcome after chemotherapy (Santini et al., 1989; Sargent & Taylor, 1989; Hongo et al., 1990; Pieters et al., 1991; Kaspers et al., 1993a,b) .
A disadvantage of the MTT assay, and of other assays such as the fluorometric microculture cytotoxicity assay (Larsson et al., 1992) and the INT assay (Santini et al., 1989) , is that no discrimination can be made between malignant and non-malignant living cells. Such a discrimination can be made with the differential staining cytotoxicity (DiSC) assay (Weisenthal & Kern, 1991) , but this assay is laborious and subjective ). An alternative may be the removal of contaminating mononuclear cells from malignant samples.
We previously reported that normal peripheral blood lymphocytes are more resistant to drugs than untreated childhood acute lymphoblastic leukaemia (ALL) samples (Kaspers et al., 1991) . Therefore, the presence of these cells in an ALL sample will influence the MTT assay results. It has been shown that when 80% or more leukaemic cells are present in the sample at the start of the assay, the MTT assay and DiSC assay provide similar results (Pieters et al., 1989; Kirkpatrick et al., 1990 ). However, one should also consider the percentage of leukaemic cells after culture, because a decrease in this percentage may influence the assay results. We studied in 106 untreated childhood ALL samples whether a decrease in the percentage of leukaemic cells had occurred after culture, and whether this influenced the drug resistance profile. We also investigated in another group of untreated or relapsed ALL samples whether contaminating mononuclear cells could be removed by using immunomagnetic Dynabeads. This may increase the number of samples which can be evaluated for cellular drug resistance using the MTT assay or similar drug resistance assays.
Materials and methods

Cells
Mononuclear cells were isolated from the bone marrow or peripheral blood samples by Ficoll density-gradient centrifugation (Ficol Paque; density 1.077g ml-'; Pharmacia, Sweden) for 15 min (room temperature, 1,000 g), washed twice, and resuspended in RPMI-1640 (Dutch modification, Gibco, Uxbridge, UK). The medium contained 20% fetal calf serum (Flow Laboratories, Irvine, UK) and several other supplements .
A total of 106 samples from children with newly diagnosed Cell culture drug resistance assay We used the colorimetric MTT assay, as described previously . Briefly, ALL cells were cultured in the wells of microculture plates for 4 days at a final concentration of 1.2-1.6 x 106 cells ml-', with or without cytotoxic agents. The 106 untreated childhood ALL samples were tested with up to 13 drugs, depending on the number of cells available: prednisolone (concentration range 0.05-1,500 fig ml-'), dexamethasone (0.0002-6Lg ml-'), vincristine (VCR, 0.05-50 1g ml1'), vindesine (0.05-50 fLg ml'), daunorubicin (0.002-2 ig ml-'), doxorubicin (0.008-8 tg ml-l), mitoxantrone (0.00l-ljgm11'), L-asparaginase (0.003-10IUml-'), mercaptopurine (6MP, 15.6-500 g m1'I), thioguanine (1.56-50 tgm1mP), teniposide (TEN, 0.003-81agmlm'), cytarabine (ara-C, 0.002-2.5 fg ml-') and 4-hydroperoxyifosfamide (4-HOO-ifosfamide, 0.1-100 gg ml-'). The samples used for the experiments with the immunomagnetic beads were usually tested with only 4-5 drugs, because of the lack of material. Most drugs were obtained from the hospital pharmacy, except that 6MP, thioguanine and doxorubicin were from Sigma (St Louis, MO, USA) and 4-HOOifosfamide was a gift from ASTA Pharma (Dr M. Peukert, Bielefeld, Germany). After the incubation period, MTT (Sigma) was added to all wells and the plates were again incubated for 6 h. The formed formazan crystals were dissolved with acidified (0.04 N hydrochloric acid) isopropanol, and the optical density in each well was Per cent ALL cells, day 0 Figure I Percentage of ALL cells before and after 4 days of culture in 106 untreated childhood ALL samples. The line shows the cut-off level (70%) below which we consider the results for samples not evaluable when the MTT assay is used. (Table II) . There was no significant relation (Mann-Whitney U-test) between treatment outcome and cell viability (P = 0.67) or MTT-specific activity (MTT dye reduction capacity, P = 0.82). The relation between drug resistance profiles and treatment outcome will be the subject of another report. There was also no correlation between cell viability or MTTspecific activity with in vitro drug resistance (data not shown).
Removal of mononuclear cells using immunomagnetic Dynabeads The influence of this procedure on the results of the MTT assay was studied in three ALL samples with > 95% leukaemic cells after isolation. Each sample was divided in two; one half was exposed to Dynabeads as described above and one half was not. For all three samples, dose-response curves for the four drugs tested were very similar for the ALL cells which had been exposed and those which had not been exposed to Dynabeads. This is illustrated in Figure 2 for one of these patients. In addition, the procedure did not change the optical density of control wells (cells, no drugs), and was not cytotoxic to the ALL cells as determined by trypan blue exclusion. Whether the removal of mononuclear cells from ALL samples actually resulted in a change in drug resistance profile-towards a more sensitive profile-was tested by a paired comparison in one sample. The results showed this indeed to be the case (Figure 3) . This was later confirmed in two additional samples.
In 24 out of 30 samples the percentage of leukaemic cells was > 80% at the start of culture, that is after the Dynabeads procedure. Two (9%) out of these 24 samples, both from patients with relapsed pre-B-ALL, showed a decrease below 70% (62% and 49%) leukaemic cells after culture. This frequency of 9% is similar to that of 13% in samples not exposed to Dynabeads, as mentioned above. The Dynabeads procedure did not have a significant adverse effect on the control cell viability in drug-free wells after 4 days of culture (mean 54.8%, s.d. 18.4%), as compared with the control cell viability in the 106 untreated ALL samples not exposed to Dynabeads (mean 63.0%, s.d. 28.9%). taminating an ALL sample, using immunomagnetic beads, on cellular drug resistance. Drug concentrations increase from A to F (Materials and methods). The part of the ALL sample not exposed to beads contained 61% leukaemic cells after culture, and showed a more resistant profile than the part of the ALL sample which was exposed to beads, and which contained 96% leukaemic cells after culture. For (Pieters et al., 1989; Kirkpatrick et al., 1990) . The MTT assay can therefore be used to determine the drug resistance profile of untreated ALL samples with > 80% leukaemic cells present at the start of culture, and the results should not be considered evaluable in the case of the presence of <70% leukaemic cells after culture. These cautionary notes also apply for other cell culture drug resistance assays in which no distinction can be made between malignant and non-malignant cells. The cut-off points of 80% and 70% might also be appropriate for relapsed ALL samples and acute non-lymphoblastic leukaemia samples. These samples are generally not more drug sensitive than untreated ALL samples; in fact, they are significantly more resistant to certain drugs (Kaspers et al., 1994; Klumper et al., 1993) . Therefore, contamination with mononuclear cells is less likely to result in a false, over-resistant drug profile than in the case of untreated ALL samples, assuming that similar percentages of leukaemic cells are present in these leukaemia samples.
One alternative way to determine the drug resistance profile of samples with < 80% ALL cells is the DiSC assay, which distinguishes drug effects on malignant and nonmalignant cells (Weisenthal & Lippman, 1985) . The procedure of the DiSC assay is similar to that of the MTT assay until the moment of adding MTT to the wells. In fact, it is possible to first determine the percentage of leukaemic cells after culture, and only then to decide to use the MTT assay, in the case of > 70% leukaemic cells, or the DiSC assay, in the case of < 70% leukaemic cells. However, the DiSC assay is laborious, subjective and requires skilled technicians (Pieters, 1989; Weisenthal & Kern, 1991) . Alternatively, one may decide to use shorter drug incubation periods. However, in that case higher drug concentrations are needed to give significant cell kill in ALL samples (Pieters et al., 1988) . Such concentrations would far exceed clinically achievable peak plasma levels.
Another alternative would be to remove contaminating non-malignant cells to enable the use of the MTT assay for samples with initially <80% leukaemic cells or even for samples with 80-90% leukaemic cells. A marked part of these latter samples will show a decrease below 70% leukaemic cells after culture. We investigated the removal of mononuclear cells by immunomagnetic Dynabeads. These magnetic beads have been used for purging (Shimazaki et al., 1988; Gruhn et al., 1991) , T-cell depletion of bone marrow grafts (Vartdal et al., 1987) , removal of leucocytes from renal carincomas prior to chromosome studies (Linehan et al., 1989) and purifying ALL samples by removing Tlymphocytes and monocytes for proliferation studies (Skj0nsberg et al., 1991) . In the present study it appeared to be possible to increase the percentage of leukaemic cells to > 80% in 17 out of 22 ALL samples by Dynabeads. The mean increase of the percentage of leukaemic cells after the Dynabeads procedure was 15%. The mean recovery of viable leukaemic cells was ± 80%, i.e. 20% of the cells were lost. The procedure with Dynabeads did not alter the drug resistance profile of the leukaemic cells and had no adverse effect on the success rate of the MTT assay as compared with normally processed samples. It even diminished the number of dead cells in the sample. In our laboratory, we now use Dynabeads in 15-20% of all samples received for drug resistance testing. Criteria to use beads are the presence of at least 5 x 106 leukaemic cells and the presence of > 10% potentially removable contaminating cells. In our experience, the use of beads increases the percentage of samples with evaluable MTT assay results from 70 to 80%. These criteria and the effect on the evaluability rate of the MTT assay may differ between laboratories, and for instance largely depend on the type of malignant samples tested.
We conclude that a decrease in the percentage of leukaemic cells can occur during the culture of untreated childhood ALL samples. This decrease should be monitored if a sample is studied using the MTT assay or a similar assay, because the results are significantly influenced in case of a decrease below 70% leukaemic cells after culture. Removal of contaminating mononuclear cells is feasible using immunomagnetic Dynabeads, without an adverse effect on the leukaemic cells itself. Such a removal will increase the number of leukaemia samples which can be evaluated for cellular drug resistance using the MTT assay. This study does not answer the question whether this approach provides more reliable results for individual cases than the DiSC assay.
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